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1INTRODUCTION
The true prevalence of atherosclerotic renal artery stenosis (ARAS)
is higher than the number reported because of the lack of specific clinical
symptoms and signs and lack of appropriate guidelines for evaluation of
ARAS. Early identification of ARAS helps in preventing the renal and
cardiovascular morbidity and mortality.
There is sparse available Indian literature about the occurrence of
ARAS in CAD individuals. This study intends to study the percentage
and predictors of ARAS in CAD individuals undergoing CAG in
Government Stanley Hospital, Chennai. Identifying clinical risk factors
would enable stratifying patients and identifying those patients in whom
screening renal angiography would be indicated.
2REVIEW OF LITERATURE
Renovascular disease is the occlusion of renal arteries or of one of
its branches by atherosclerotic, fibromuscular, or inflammatory lesions,
which may lead to renovascular hypertension, pulmonary edema or renal
failure, referred to as ischaemic nephropathy. [2]
NORMAL ANATOMY
The kidneys are located against the posterior abdominal wall
against T12- L3 vertebrae. The kidneys are retroperitoneal organs. It is
bean shaped.  The hilum on the medial  border is  the site  where the renal
artery, renal vein and the ureter are located. It has the renal lymphatics
and nerves also. At the superior border is the adrenal gland.
Each kidney is enveloped by the following coverings: The inner
renal capsule, the middle adipose capsule and the outer renal fascia.
A coronal section of the kidney show kidneys, the outer renal
cortex, adjacent to the renal capsule, which is granular in appearance and
composed of capillaries and the inner medulla made of conical pyramids.
The apices of the renal pyramids are called as renal papillae. The
collecting system of the kidney consists of the minor calyx, major calyx
followed by the ureter.
3Figure 1: Anatomy of the kidney. (a) & (b): Gross anatomy of the
kidney, (c): Structure of a nephron
The nephron is the structural and functional unit of the kidney that
performs the function of filtration and concentration of urine prior to
excretion.  The  Gross  anatomy  of  the  kidney  and  the  structure  of  a
nephron are shown on Figure 1.
4RENAL BLOOD VESSELS
The kidney is rich in vascular supply which allows continuous
cleansing and modification of large volumes of blood. The descending
aorta gives rise to the main renal artery.
The renal artery branches into interlobar arteries that lead into
arcuate arteries that lead into interlobular arteries. Microscopic afferent
glomerular arterioles arise from branches of the interlobular arteries. The
afferent glomerular arterioles transport blood into the glomeruli.
The blood remaining in the glomerulus leaves after filtration passes
through the efferent glomerular arterioles. From these capillary systems,
blood drains into veins which parallel the course of the arteries in the
kidney, namely the interlobular veins, arcuate veins, and interlobar veins.
The interlobar veins run in between the renal pyramids, converge, and
leave the kidney as the renal vein that drains into the inferior vena cava.
Each kidney is supplied by the corresponding renal artery but there
can be anomalous accessory renal arteries in 20- 30% patients. In a
resting adult, the kidneys receive 1 to 1.4 L of blood per minute, or just
under 25% of the cardiac output.
5Figure 2: Renal Blood Vessels
Figure 2 shows the renal artery that enters at the renal hilum and its
course in the renal cortex and medulla that eventually leads into the
venous system which finally converge into the renal vein that exits at the
hilum.
NORMAL PHYSIOLOGY
When the two kidneys normally function, their capacity of
performing the function of excretion is twice of what the body requires to
6maintain homeostasis. But with aging due to decrease in renal blood flow,
the function deteriorates to 45% of normal by the age of 80 years.
Blood flow (Q) in a vessel is given by Darcy’s law, Q=?P/R,
where ?P is the pressure difference between the two wends of the vessel
and R is the vascular resistance. [3] The vascular resistance increases when
the flow is turbulent, by obstruction to the flow. Compensation to lumen
stenosis happens upto a certain extent by increase in the flow velocity.
RENAL AUTOREGULATION
When the kidney is perfused at moderate pressures (90-220 mm Hg
in the dog), the renal vascular resistance varies with the pressure and the
renal blood flow is almost constant. It is proposed to be due to a direct
contractile response of the afferent arteriolar smooth muscle to stretch
mediate by Nitrous Oxide and angiotensin II.
PATHOPHYSIOLOGY OF ATHEROSCLEROTIC RENAL
ARTERY STENOSIS (ARAS)
Renal artery stenosis (RAS) is an abnormal change in the vascular
lumen which becomes hemodynamically significant when reduced
>50%.[4] Critical RAS occurs when the renal arterial lumen is reduced by
more than 60%. Critical stenosis refers to the degree of stenosis at which
7flow and pressure begin to be reduced, any further increase in stenosis
would significantly decrease the flow and pressure.
ETIOLOGY OF RAS
The most common cause of RAS is atherosclerosis followed by
fibromuscular dysplasia. Critical (>60%) stenosis is observed in 9% men
and 5.5% women over 65.[5] The occurrence is higher in those individuals
with coronary (19%) or peripheral (35–50%) vascular disease.
PREVALENCE OF ATHEROMATOUS RENAL ARTERY
STENOSIS[4]
i) 25% of autopsy samples
ii) 24% patients undergoing renal angiography during cardiac
catheterisation
iii) 45- 50% patients having peripheral vascular disease
iv) 15% patients undergoing renal dialysis
ARAS occurs in the middle-aged and elderly, most commonly
male smokers. Bilateral involvement is seen in 50% cases.
The aortic ostium is the most frequent anatomic location. It occurs
because  of  the  rapid  blood  flow through  the  renal  artery  due  to  the  rich
vascular supply and also the angulation at the renal artery origin.
8Turbulent flow causes endothelial injury at this site, that predisposes to
atherosclerosis at the site.[4]
BURDEN OF ARAS IN INDIA
Renal artery stenosis due to atherosclerosis is more frequent than
those reported. Coronary artery disease is prevalent among 10% of urban
Indian population and 8% of patients undergoing coronary angiography
have significant ARAS.[6] Thus significant ARAS is estimated to be
found in 0.8% of adult urban Indian population.[6]
The prevalence of ARAS causing advanced chronic kidney disease
(CKD) or end stage renal disease (ESRD) is lower in India and found to
be  0.3%  of  the  CKD[6] and ESRD population. This shows that though
highly prevalent, only few ARAS patients actually present as advanced
CKD. This discordance could be because most ARAS patients may not
progress  to  ESRD  or  they  may  succumb  to  the  disease  before  they
develop advanced CKD. Leertouwer et al reported that none out of 126
patients with ARAS survived over 10 years and Conlon et al reported that
only one out of 188 over 4 years developed ESRD.[6]
In young women between 14- 52 years age, RAS occurs commonly
due to an intrinsic structural alteration of the arterial wall due to
9fibromuscular dysplasia, commonly seen to occur in the distal main renal
artery.
Other uncommon causes of RAS are thromboembolic disease,
vasculitis like Takayasu arteritis, Polyarteritis nodosa, post radiation,
tumours like neurofibromatosis and lymphomas compressing the renal
artery, retroperitoneal fibrosis or iatrogenic restenosis following
angioplasty or other renovascular surgery. [7]
Figure 3: Common sites and etiology of Renal artery stenosis
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NATURAL HISTORY
Atherosclerotic RAS is a generalised gradually progressive disease.
High risk of progressive obstruction is observed in individuals with high
systolic blood pressure, diabetes mellitus and those with pre-existing
stenotic renal artery
Figure4: Shows the progression of RAS and associated renal changes
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PROGRESSION OF ARAS
Caps et al assessed the temporal profile of ARAS in 295 kidneys in
170 patients over 33 months.[8] Progressive vessel occlusion was
measured to be a rise in the renal artery peak systolic velocity (RAPSV)
of >0.1m/sec relative to the original value or complete renal artery
obstruction. On a 3 year follow up, the incidence of renal artery stenosis
in renal arteries found to be normal, less than 60% obstruction and
>obstruction are 17%, 30% an 48% respectively.[8]
The group also analyzed the risk of renal atrophy (reduction in the
length of the kidney by >1 cm). The cumulative incidence of renal
atrophy was found to be significantly higher in ARAS >60% compared to
normal or ARAS <60% initially. Multivariate regression analysis
concluded that increase in RAPSV predicted renal atrophy, but not
systolic blood pressure or renal cortical end diastolic velocity. [8]
Also serum creatinine in these patients who developed atrophy of
both kidneys increased by a just 0.33 mg/dl/ year when compared to those
who had no atrophy in both kidneys. These observations indicate that
progression of ARAS is not necessarily associated with decline in GFR.
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POISEUILLE’ S EQUATION
For a steady laminar flow of homogenous fluid through a straight
tube with rigid walls, blood flow(Q) is given by,
Q = ??Pr4/(8L)
where ?P= pressure gradient, r= radius of the tube, L= length of stenosis,
= fluid viscosity.
Thus the primary factor determining the blood flow through a
vessel is the diameter of the vessel. However the resistance in a blood
vessel due to a stenosis is much higher than that predicted by Poiseuille’s
equation because the blood flow through a blood vessel is i) turbulent, ii)
pulsatile and iii) blood is a nonhomogenous fluid with blood cells
suspended in plasma.
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HEMODYNAMIC EFFECTS DUE TO RAS
The hemodynamic changes in pressure and flow occur occur only
beyond critical stenosis. The degree of stenosis which should occur to
cause critical stenosis is determined by vascular resistance in the kidney,
flow velocity, viscosity of blood and the number of stenotic sites in the
vessel.
Once critical stenosis occurs the relation between the radius of
stenosis and the pressure drop is exponential. Distal to the site of critical
stenosis both blood pressure and flow are decreased in parallel. For RAS
to cause renal hypertension and renal failure, the glomerular filtration
pressure should fall.
The principal humoral and hemodynamic changes occurring due to
RAS[4,10]:
1. Ischemia induced nephron loss
2. The stenotic kidney produces renin secretion
3. Angiotensin II induced vasoconstriction and hypertension
4. The renin secretion from the other kidney is reduced
5. Intrarenal vasoconstriction and so decreased renal blood flow
6. Aldosterone production is increased
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7. Increased sodium and H2O retention due to stimulation of the renin
angiotensin system.
MECHANISMS CAUSING TISSUE INJURY IN ARAS
ARAS not only endangers renal function but also causes worsening
of cardiac function. The pathogenetic mechanisms leading to these
changes are being studied.
Atherosclerotic renovascular disease causing renal artery stenosis
is not the only abnormality causing renal injury. There is no significant
correlation between the amount of obstruction and the degree of renal
injury.
Due to the renal artery stenosis there is hypoxia, oxidative stress,
and a fall in renal perfusion pressure, dyslipidemia, increase in
atherogenic factors in the circulation beyond the stenosis there is
abnormal stimulation of the renal angiotensin aldosterone system that
lead to the kidney injury observed.[9,13] Endothelial damage, decreased
nitric oxide mediated vasodilation and large amounts of vasoconstricting
substances cause large amount of free radical generation and oxidative
stress.[9,10]
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RAS AND VASCULAR ENDOTHELIAL GROWTH TO THE
FACTOR (VEGF)
VEGF causes new blood vessel formation and for preserves the
existing visceral blood vessels.[11,14] It plays a vital role in formation,
reparative mechanisms and maintenance of the microvasculature of all
organs including the kidney. VEGF prevents scar formation in the kidney.
The kidneys constitutively produce VEGF that acts on endothelial
cells predominantly. Studies show that the reduced VEGF and so reduced
microvascular density in RAS caused significant scarring of the renal
tissue due to high renal vascular resistance, decreased renal blood flow
and GFR.[11,12,15]
In the early stage of RAS, the local vascular supply i.e. blood
supply/kidney tissue is preserved because of the fall in size of the kidneys
and the microvasculature and renal blood flow. At a later stage, this
compensatory mechanism does not act. Deleterious changes occur in the
other kidney later stage contributing to the worsening of hypertension and
subsequent renal damage.
Available literature shows that VEGF administration, increased the
cortical and medullary microvascular density and significantly increased
regional vascular supply and also helps to preserve the homeostasis of the
16
affected kidney. VEGF thus preserves pre-existing vessels and causes
formation of fresh vessels.
CLINICAL PRESENTATION OF RAS
The salient clinical features of RAS are:
i) Renovascular hypertension
ii)  Renocascular azotemia referred to as ischemic nephropathy
iii)  Recurrent pulmonary edema
iv)  Secondary hyperaldosteronism
i) RENOVASCULAR HYPERTENSION
It accounts for 1 to 5% of all hypertension cases[12]. The
presentation is malignant or resistant hypertension commonly. Many
patients with renovascular hypertension have hypertension not responsive
to an appropriate regimen containing a combination of 3 drugs, in
association with renal failure or with atherosclerosis at other vascular
territories.
The mechanism of hypertension in ARAS is complex [9,12]. Animal
studies show that a fall in the perfusion of the kidneys causes a series of
events. There is synthesis of renin. Renin causes Angiotensin I from
Angiotensinogen that is converted to Angiotensin II by Angiotensin I
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converting enzyme. This angiotensinII deactivates kinins and thus
promotes fall in blood pressure.
By directly causing vasoconstriction and hence hypertension, in
addition angiotensin II increases total blood volume and thus promotes
hypertension by its action on aldosterone and by promoting the
vasoconstriction caused by norepinephrine.
The early phase of renovascular hypertension occurs due to
activation of the the Renin Angiotensin aldosterone system and retention
of sodium and water  and expansion of  extracellular  fluid volume. In the
chronic phase hypertension is volume dependent and renin release is
suppressed.
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Figure 5:
Describes the the various mechanisms mediating renovascular
hypertension. The complex mechanisms mediates changes in the
kidney, the vascular system and the heart.
19
Figure 6:
Demonstrates the sequence of events occurring after acquiring
atherosclerotic risk factors contributing to renal injury
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Goldblatt's study describes 3 stages of renovascular hypertension in
animal studies[10]:
i) Stage 1:
Sudden onset obstruction
ii) Stage 2:
Obstruction for a few days. Hypertension occurs and the plasma
Renin and Angiotensin II levels rise, and clearing the occlusion
causes the normotension and plasma Renin and Angiotensin II
levels to normalise.
iii) Stage 3:
Obstruction lasts > 1 month. Plasma Renin and Angiotensin
levels are normal. Removal of the obstruction does not cause
the blood pressure to normalise.
Stage III reflects hypertension observed in patients with ARAS
who are not strictly renin dependent[10]. ARAS sufferers with
low renin and angiotensin II levels have a clinical improvement
in blood pressure control after renal revascularization, but the
beneficial outcome should be validated by future studies.
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The Renin angiotensin aldosterone system mediated pressor effects
and the increase in total blood volume mediated by stimulation of
the sympathetic and central nervous system cause hypertension in
ARAS.
Existing literature says that ARAS results in significant
cardiovascular consequences significantly more than the severity of
hypertension. Multiple mechanisms contribute to this. Angiotensin
II is associated with numerous proinflammatory and damaging
cardiovascular effects like myocardial fibrosis, arterial medial
hypertrophy, endothelial cell dysfunction, smooth muscle cell
proliferation, and plaque rupture.
Oxidative stress also seems to play a role in the hypoxic ischemic
and hypertension mediated renal parenchymal injury in ARAS.
II) RENOCASCULAR AZOTEMIA REFERRED TO AS
ISCHEMIC NEPHROPATHY:
RAS may cause acute kidney injury and chronic renal failure.
Acute kidney injury occurs in patients with vascular obstruction to
a single functioning kidney or bilateral RAS taking medications
blocking the renin angiotensin system. In most others it causes
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glomerulosclerosis and chronic renal failure progressing to end
stage renal disease. Most commonly causes a bland urine segment
and non nephritic range proteinuria.
III) RECURRENT PULMONARY EDEMA
Recurrent acute onset flash pulmonary edema occurs due to
retention of fluid and ventricular diastolic dysfunction.
IV) SECONDARY HYPERALDOSTERONISM
Associated with with low plasma sodium and potassium.
Clinical examination mostly reveals bruits over major vessels such
as the abdominal aorta due to widespread atherosclerosis. The classical
lateralising renal artery bruit is rare.
NEED TO SCREEN FOR ARAS
Early identification of RAS is important for the following reasons:
- Pharmacological management of RAS is difficult.
- High renin hypertension has higher rates of cardiovascular and
cerebrovascular complications.
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- Being a correctable cause of high blood pressure and terminal renal
failure be identified and treated.
- Being a progressive disease and warrants early identification for
better prognosis
Early  identification  of  RAS  can  enable  detailed  evaluation  of  the
renal artery anatomy, localisation of the lesion and timely intervention
can help in avoiding complications and better prognosis.
ASSOCIATION OF ARAS and CAD
More than 50% ARAS patients develop ischemic heart disease or
need cardiac revascularization procedures more frequently than non
ARAS patients. The simultaneous occurrence of ARAS accelerates and
worsens coronary artery disease and confers lower survival rates despite
coronary revascularization.[16,17,18,19] ARAS does not have any specific
symptomatology and there are no established guidelines for management
of ARAS and hence it continues to remain unrecognized for a long time
in the course of the disease.
Aetiopathogenesis of ARAS and CAD are similar and hence a
significant association has been found between them.[17,18] Early attention
to the kidney abnormality is associated with good blood pressure control,
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normal renal function and a better outcome after coronary
revascularisation procedures in CAD. The renal angiogram with
angioplasty/stent can be done simultaneously using the equipment
adapted for coronary angiography.
EVALUATION
ARAS is associated with advancing age, Chronic renal failure,
smoking and other atherosclerotic risk factors. These characteristics may
be associated with essential hypertension also.
The classic clinical clues that suggest the presence of ARAS are[5]:
- Onset of stage 2 hypertension > 50 years without any other family
members having high blood pressure
- Together with renal failure (especially if renal failure increases
after the use of renin angiotensin aldosterone system blockers)
- Recurrent flash pulmonary edema
- And drug-resistant hypertension
On  clinical  suspicion  of  ARAS,  the  diagnosis  is  confirmed  by
imaging as biochemical investigations such as plasma renin measurement
confirmation are non specific.
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SCREENING TESTS
DIAGNOSIS:
- Doppler Ultrasonography
- Magnetic Resonance Angiography (MRA)
- Helical Computed Tomographic Angiography (CTA)
- Renal Scintigraphy (using Captopril scan)
- Invasive Angiography
- Peripheral Renin levels
- Renal vein Renin sampling
Can be useful to identify ARAS.
Recommendations for screening patients for ARAS[20]:
1. Onset of>grade 2 hypertension >55 years age
2. Malignant or drug resistant hypertension
3. ACE inhibitor induced worsening renal function
4. Size difference of >1.5cm between the 2 kidneys
5. Recurrent sudden onset pulmonary edema
6. Multivessel coronary artery disease or peripheral vascular
disease
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CREATININE LEVELS AND GLOMERULAR FILTRATION
RATE
It is a method of functional assessment and can quantitatively
assess efficacy of renal interventions. Significant unilateral ARAS
reduces GFR in that kidney but there is no alteration of the creatinine
concentration until reduction of half of the overall kidney mass.
Therefore the serum creatinine is not a reliable marker of the individual
renal performance and renal mass[20]. It does not reflect the GFR totally.
As the renal failure increases the creatinine correlates better with the GFR
and with kidney performance.
GFR estimation by creatinine based formulae, MDRD or
measuring GFR by iohexol clearance are relatively better indicators of
renal function.
IMAGING STUDIES
An optimal imaging modality must meet the following 4
objectives[20,21]:
(1)  ARAS must be identified and quantified based on severity
anatomically and hemodynamically.
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(2)  Anatomic effects of ARAS both on the renal artery itself and
on the kidney should be studied
(3) Effects of ARAS on the kidney at the functional and cellular
level should be assessed (by captopril renography, the
cellular viability of the renal parenchyma of chronic kidney
disease patients is determined by diffusion-weighted
magnetic resonance imaging
(4) Criteria associated with renal impairment related should be
identified.
DUPLEX ULTRASONOGRAPHY
Duplex ultrasonography the most preferred initial imaging tool for
the  detection  of  RAS,  although  less  accurate  than  CTA  and  MRA[20,22].
The advantages of preferring duplex ultrasonography is due to the
absence of risks of contrast associated illnesses like contrast induced
acute kidney injury, nephrogenic systemic fibrosis and atheroembolic
disease[21,23].
However, undue reliance on the performer’s skill, the inability to
recognising accessory renal arteries and difficulty in screening obese
patients or patients with intervening bowel gas are the limitations[20,23].
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Ultrasonography provides information on kidney size, renal
resistive index (RRI [defined as peak systolic velocity – end-diastolic
velocity/peak systolic velocity]) and renal functional reserve. A high
renal artery end-diastolic velocity (>90 cm/s) and low RRI (<75-80)
indicate that there is no microvascular disease or increased
resistance[24,25,26].
Widening of the spectrum and high velocity indicate that there is
obstruction large enough to affect the vascular flow through the
vessel[24,25,26].
The sensitivity and specificity of ultrasonography were 84% and
90%, respectively, in identifying hemodynamically significant ARAS
according to a recent literature review. [20,22]
Severe stenoses causes tardus parvus alteration on the spectrum on
Doppler ultrasonography, seen as a small systolic acceleration with a low
resistive index[25,26,27].
Features suggested for the identification of distal stenoses are[20]:
i) Obliteration of early systolic peak acceleration (<3 m/s2)
ii) Acceleration index greater than 4 m/s2
iii) Increase in time to systolic peak greater than 0.07 seconds
iv) Greater than 5% difference in RRI between kidneys
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COMPUTED TOMOGRAPHIC ANGIOGRAPHY (CTA)
ARAS usually occurs <1cm from the aortic wall. The luminal size
of the renal artery is usually 0.4–0.6 cm. With three dimensional imaging
CTA has become the ideal method for the identification of ARAS[28,29].
Because CTA radiation exposure and iodinated contrast agents, it is
should not be used in patients with contrast allergy. Contrast-induced
nephropathy associated with the use of iodinated contrast can be avoided
by adequate hydration before infusing the contrast agent. For detection of
ARAS  the  sensitivity  of  CTA  is  95%  and  the  specificity  is  62%  -
92%.[20,29,38,37]
In contrast to MRA, CTA identifies small accessory renal arteries
due to its high spatial resolution. CTA is chosen over MRA in patients
with various implants , patients who cannot hold their breath for long, and
for patients with claustrophobia. However, specificity of CTA for
detecting hemodynamically significant ARAS is less than that for MRA.
CTA images of heavily calcified arteries are difficult to interpret .
MAGNETIC RESONANCE ANGIOGRAPHY(MRA)
Magnetic resonance angiography has a sensitivity and specificity
of  >90%  .[30,31] It does not require iodinated contrast or radiation.
Gadolinium-based contrast medium should not be used in patients renal
failure due to potential to cause nephrogenic systemic fibrosis.
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MRA should be avoided in patients with certain implanted devices
or in patients with claustrophobic . MRA has no calcification
artifact.[20,30,31,32]
Figure 7:
Magnetic resonance and computed tomographic angiography
of renal artery stenosis. (A) Demonstrates a magnetic resonance
angiogram of severe bilateral renal artery disease. The right renal
artery is occluded just after its ostium (white block arrow), and the
left renal artery has a severe proximal stenosis (white arrow). (B)
Demonstrates a processed reconstructed computed tomography
angiogram of bilateral severe renal artery stenosis, marked with
arrows to highlight the region of maximum stenosis.
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CAPTOPRIL RENOGRAPHY
This functional test detects the GFR dependence of angiotensin II.
If the test is positive by giving oral captopril of 25 to50 mg there is a
delay in the uptake of tracer and there is a drop in the maximum peak
uptake, prolongation of the duration captopril stays in parenchyma and
slow removal, and also affects function of each kidney in unilateral
disease.[20,31]
Its efficacy as a diagnostic tool drop in end stage renal failure,
bilateral disease and if there is a single functioning kidney. It is preferred
to predict the benefit from renal revascularization. But it is not advised
for routine assessment of RAS .
ANGIOGRAPHY
Angiography can assess the degree of ARAS, and also detect
vascular abnormalities and anatomic abnormalities of the kidneys and
also the aorta.[20,32,34] Digital subtraction angiography has the advantage
of improving contrast resolution and also requires less amount of
contrast. But it is an invasive procedure, and has the risks of vascular
puncture and manipulation of the vessel, that could lead to arterial
trauma, spasm, or thromboembolic phenomenon. Carbon dioxide can be
utilized in patients with kidney dysfunction or contrast allergy.
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White  et  al  study  has  proven  that  there  is  the  possibility  of
significant observer differences in the estimation of degree of stenoses in
coronary artery disease manually, that could also apply to the
measurement  of  ARAS.  Thus,  to  rely  completely  on  angiography  to
quantify ARAS is not ideal, and additional methods should be used
together to determine if there is renal injury.[32,35,36,38]
The pressure difference across the area of stenosis could be
estimated angiographically to estimate hemodynamic effects prior to
therapeutic interventions such as percutaneous transluminal renal
angioplasty (PTRA) or stenting.[20,33,35]
De Bruyne et al found that obstruction with a distal to proximal
renal artery pressure fall >10% caused more Renin secretion and thus
proved that calculation of the pressure difference across the area of
stenosis might help to study hemodynamically significant ARAS.[20,33,37]
MEDICAL THERAPY
Aggressive medical therapy can lead to improvement of ARAS
patients. Use of angiotensin-converting enzyme inhibitors and
angiotensin receptor blockers is advised for controlling hypertension and
for improving outcome.[39] A drop in the kidney function after initiating
these drugs is seen in bilateral RAS .
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Timely administration of statins for optimal lipid levels,
maintaining optimal glucose levels, and stopping cigarette smoking are
important. No validated study has studied the effects of drug therapy on
the management of renovascular hypertension as these patients often
present as refractory hypertension and need combination therapy.[39]
Medications that block the renin-angiotensin-aldosterone system
(RAAS) are preferred to manage high blood pressure in patients with
ARAS, but they can predispose to acute kidney injury, in individuals
severe bilateral ARAS, severe obstruction of a single existing kidney or if
the other kidney is  atrophied,  or  end stage chronic renal  failure due to a
fall in the perfusion pressure. Serial monitoring of the renal function is
important as acute impairment in renal function due to these medications
can frequently be reversed by prompt discontinuation of the offending
agent.
Some studies have proved that individuals with high RRI (>80)
benefit better with drug therapy than revascularization; however, using
the RRI as the only indicator of medical therapy is debatable.[39,40]
Calcium channel blockers maintain renal blood flow by decreasing
the tone of afferent arterioles and beta blockers lower renin.
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Patient prognosis is good when agents that block the Renin
Angiotensin Aldosterone system is used for treatment. Simultaneous use
of diuretic agents should be avoided. The drug should be discontinued the
serum creatinine rises more than 20% and interventional vascular therapy
should be planned.
If both kidneys are involved or there is obstruction to a single
kidney, ACE inhibitors should be used with caution, as renal failure can
occur due to the dilation of the efferent arterioles that causes the capillary
pressure in the glomerulus to fall less than the minimum required value
and acute kidney injury can result <2 weeks after use of these drugs.
RENAL ARTERY REVASCULARIZATION
Successful percutaneous revascularization have not always given
clinical benefit. Therefore if therapeutic revascularisation is indicated in
ARAS and hypertension is debatable.
American Heart Association definition of significant RAS is as
follows[20,40,42]:
(1) Occlusion of 50% - 70% lumen size by direct visual estimation
with a peak translesional pressure difference > 20 mm Hg or a
mean pressure difference of >10 mm Hg
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(2) Occlusion 70% of vessel diameter
(3) Stenosis >75% diameter by ultrasonography done through the renal
artery
But as per the recent American Heart Association
recommendations, revascularisation should be done only for ARAS
complicated by associated comorbidities.
Table 1: Shows the American Heart Association indications for
Revascularisation of ARAS in the following scenarios: Asymptomatic
stenosis, hypertension, renal failure and cardiac failure.
36
When interventional vascular therapy is contemplated , the severity
of underlying nephropathy should be determined. ARAS with end stage
renal disease do not significantly improve after revascularization.
The predictors of advanced nephropathy are:
1) Protein loss greater than 1000m g/d)
2)  Kidney size < 10 cm
3)  RRI > 0.8
4) Kidney biopsy demonstrating advanced nephropathy
The serum creatinine level is not a suitable marker of nephropathy.
PERCUTANEOUS TRANSLUMINAL RENAL ANGIOPLASTY
(PTRA) FOR ARAS
INDICATIONS
Management of hypertension
a. A high possibility of cure of renovascular hypertension
i. Onset of high blood pressure<30 years
ii. Recent occurrence of high blood pressure > 60 years
iii. Obstruction due to fibromuscular dysplasia
b. Blood pressure control is not responding to use of >3 drugs of
different classes at optimal doses including a diuretic
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c. Accelerated hypertension
d. Malignant hypertension with end organ damage such as cardiac
failure, neurological effects, III–IV retinopathy.
Protection of kidneys
a. Renal failure that cannot be accounted
b. Decrease in renal size while treating hypertension
c. Renal dysfunction on taking antihypertensive drugs
d. Gradual extension of ARAS
Cardiovascular disease
a. Sudden severe pulmonary edema as a consequence to heart
failure
b. Unstable angina
Dutch Renal Artery Stenosis Intervention Cooperative (DRASTIC)
study is the largest randomized trial that compared medical therapy and
PTRA of about 100 patients randomly assigned to angioplasty and drugs.
If the disease was not responding to medical therapy they were subjected
to PTRA.[20,41,43]
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Major limitations of DRASTIC study
1) Registration of patients with less than significant stenosis
2) 40% were shifted from medical therapy to angioplasty
3) Very small stent usage about 25%
Patients in the angioplasty group did not significantly improve in
terms of blood pressure or renal artery size in 1 year follow up.
RENAL ARTERY STENTING
Renal artery stenting has better success and less restenosis than
angioplasty and also higher cure rates for hypertension. Renal stent use is
safe and better than other measures to achieve blood pressure
control.[44,46]
Figure 8 : Renal artery atherosclerotic plaque (left image) and Renal
artery stent in situ to restore blood flow (right image)
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There are 2 studies comparing renal artery stenting with medical
therapy.
The Stent Placement in Patients with Atherosclerotic Renal Artery
Stenosis and Impaired Renal Function (STAR) trial studied around 150
patients with a creatinine clearance of <80 mL/min/m, RAS >50%, and
good blood pressure control was randomized to renal artery stenting
together with drug therapy or only drug therapy.[45,47]
The expected outcome is a >20% fall in GFR, and the other end
points were better overall prognosis. It proved that stenting with drug
therapy caused no significant improvement in renal function but caused
life threatensing complications.
Limitations of the study
1) Patients without ARAS were wrongly identified as having ARAS
>50% by screening tests and there was no need for stenting, but
were intentionally treated in the stent group
2)  33% study participants had only minimal RAS between 50% and
70% and greater than 50% patients had involvement of a single
kidney. Because the primary end point was an improvement in
functional performance of the kidney, these patients did not benefit
much from interventional vascular therapy.
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The Angioplasty and Stenting for Renal Artery Lesions (ASTRAL)
trial studied 806 subjects with ARAS subjected to renal revascularization
plus drug therapy or only drug therapy. The primary outcome evaluated
was the performance of  the kidney and secondary outcomes were blood
pressure control, time taken for complications to occur. The patients were
followed up for nearly 3 years. No significant clinical benefit from
revascularization was observed in patients with ARAS but the associated
risks proved significant.[46,47,48]
Limitations of the study
i) Study participation was limited to patients who were on an
ii) Uncertain treatment protocol and this led to strategy selection
bias .
iii) 20% of patients had normal kidney performance, many patients
had involvement of a single kidney and about 40% had a mild
to moderate stenosis. It was concluded that the negative results
were largely due to the high registration of patients with
involvement of a single kidney who would benefit much from
revascularization.
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iv) No suitable apt investigations and imaging studies enables
accurate and unbiased recognition.
In the follow up period >50% of centers enrolled less than a patient
in a whole year, due to significant adverse effects incidence. The findings
of this trial indicate that use of renal stents offers no significant advantage
for patients with RAS but cause significant risks.
Figure 9: ASTRAL Trial results comparing medical therapy and
renal artery stenting
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The CORAL (Cardiovascular Outcomes in Renal Atherosclerotic
Lesions)  study  tries  to  analyze  the  benefits  of  PTRA  with  stenting
together with drug therapy to medical therapy based on comparing
complications.[47,48]
The study observed that prior trials lacked timely optimal drug therapy
and lifestyle changes that could have halted the development of
cardiovascular and renal ailments in this population. Therefore, CORAL
trial emphasises on :
- Strict control of blood pressure by medications
- Avoidance of smoking
- Optimalisation lipid and glucose levels by appropriate therapy
- Administration of an antiplatelet agent
The clinical benefits of these interventions has not been established
by population studies.
OTHER INTERVENTIONS
Brachytherapy and cutting balloon atherotomy can be tried for
renal artery in-stent restenosis. The clinical benefits of these measures are
unclear.[20]
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Drug delivery stents used for coronary vessels can also be used for
small renal arteries.[20] The optimal drug dose of the delivered drug for
this vessel is not established.
The biggest drug eluting stent made is <0.4cm in diameter, that is
of a smaller size than the renal artery ( normal diameter of 0.5 to 0.7 cm).
Distal embolic protection devices can also br tried for removing
atherosclerotic debris to stop it from distal embolisation. This helps to
keep the renal function normal.
SURGERY
The results of surgical revascularization for ARAS have been
good. But they are associated with significant morbidity and mortality
relative to stent placement.
Very few literature sources are available for the comparison of
surgical and percutaneous revascularization for management. In the
Balzer  et  al  study,  no  the  long  term  outcome  of  the  2  modes  of
vascularisation proved to be similar[20]. But patients managed by surgery
had a more reliable outcome. In terms of blood pressure regulation both
were  similar.  The  results  of  the  study  reveal  that  surgical
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revascularization may be atleast equally effective as to PTRA for ostial
ARAS.
Thus all patients with ARAS should be adequately managed
medically. Early identification and timely medical treatment of ARAS
avoids further cardiovascular complications. The benefits of
revascularization are unclear.
Revascularization is indicated only in special situations like
unstable angina, unexplained recurrent pulmonary edema, and
hemodynamically significant ARAS associated with renal failure or
resistant hypertension. Revascularization therapy has a vital role in the
management of ARAS, but studies indicate that its use should be
restricted to patients with renal ischemia with viable kidney function
because only these patients receive the greatest clinical outcome.
45
FIGURE 10: MANAGEMENT PROTOCOL FOR RENAL
ARTERY STENOSIS
DIAGNOSIS AND TREATMENT
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CORONARY ANGIOGRAPHY
It is the gold standard investigation of choice for confirming and
localizing coronary artery disease.
The American College of Cardiology (ACC) has prescribed
clinical scenarios when Coronary angiogram should be done.
INDICATIONS FOR CORONARY ANGIOGRAPHY
CLASS I: General consensus is that there is an indication for
Coronary angiography
CLASS II: Diverging opinions exist about the need for coronary
angiography
CLASS III: Angiography should not be performed
Indications for Coronary Angiography
CLASS I:
- Acute coronary syndrome not responding to medical therapy
- Myocardial infarction with cardiogenic shock
- Myocardial infarction(MI) panned for Percutaneous coronary
intervention (PCI)
- Continuing chest pain after fibrinolysis
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- Abnormal stress exercise test after fibrinolysis
- Congestive cardiac failure with angina
- Abnormal chest pain<9 months of PCI
- Stress test is positive and patient has high-risk features
- Sudden cardiac death or ventricular arrhythmia without a
predisposing illness
- Congestive cardiac failure with angina or ischemia
- Patient requiring valve surgery or repair of a congenital defect,
with angina
- Suspected stent occlusion
- Before repair of a mechanical complication of MI
- Planned vascular surgery with angina or positive stress test
CLASS II:
- Acute Coronary Syndrome responding to medical therapy
- If reperfusion has not occurred after fibrinolysis after ST elevation
MI
- Deteriorating ischemia after noninvasive testing
- Perioperative Myocardial infarction
- Positive stress test with no high-risk features
- Angina that is intolerant or unresponsive to medication
- Post cardiac transplantation every year for follow up
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CLASS III:
- Patient does not prefer invasive vascular therapy
- Patient has medical comorbid illness not suitable for invasive
vascular therapy
-  Within 24 h of fibrinolysis with no evidence of ischemia
- Screening of asymptomatic patients
Scenarios when Coronary Angiography should not be done:
- Kidney dysfunction
- Bleeding Tendencies
- Any active bleeding source
- Fever or active infection
- Aortic valve vegetation
- Anemia
- Severe dye allergy
- Metabolic abnormalities
- Hyperkalemia
- Hypokalemia
- Digitalis toxicity
- Uncontrolled hypertension
- Decompensated heart failure
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- Uncontrolled tachyarrhythmia
- Untreated high-grade heart block
The only absolute contraindication to coronary angiography is
patient refusal.
PREPROCEDURAL MEDICATION
1) Aspirin, 325 mg administered to eligible patients before
angiography if angioplasty is indicated.
2) If the probability of percutaneous intervention seems high, a
loading dose of Clopidogrel, 300 mg, can also be given.
3) Metformin (Glucophage) should be discontinued on the day of the
procedure, because this medication may cause lactic acidosis if
renal failure results from the procedure and if metformin is
continued after the onset of renal failure.
4)  Warfarin should be stopped before the procedure if possible until
the international normalized ratio is less than 1.8. If anticoagulation
is  essential,  warfarin  can  be  stopped  several  days  before  the
anticipated procedure, and subcutaneous injections of the low-
molecular-weight heparin, enoxaparin (1 mg/kg twice daily), can
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be substituted; the dose of enoxaparin can then be withheld the
morning of the procedure.
CONTRAST AGENTS USED
Iohexol, iopamidol, metrizamide, and ioversol are the nonionic,
low-osmolal agents used today. Intravenous hydration with normal saline
or 0.45% saline and maintenance of adequate hydration (100 mL fluid per
hour or more) during and after the procedure reduce the risk of worsening
renal function in patients with baseline renal insufficiency, particularly
diabetic patients at risk of renal failure.
Concomitant nephrotoxins should not be administered. When renal
failure occurs, it may not manifest for 24 to 48 hours. Hence, the
creatinine measurement the morning after the procedure may be of
limited value. The rise in creatinine may not occur until at least 24 hours
after the procedure, peaking approximately 5 days after the procedure,
and, commonly, resolving by the tenth day. However there is no
occurrence of renal failure with use of nonionic contrast agents.
Acetylcysteine has been shown to reduce the occurrence of contrast
nephropathy in small studies. It is important to limit the quantity of
contrast agent used in patients with chronic renal insufficiency. Limiting
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the quantity of dye to less than 30 mL markedly decreases the need for
subsequent dialysis .
VASCULAR ACCESS
Performed through the Femoral Artery or the Radial Artery
FEMORAL ARTERY ACCESS
Most commonly used access route across the globe. Catheter
manipulation is easier relative to the radial access.
Figure11: Demonstrates the route of access to the coronary
arteries through the femoral artery
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RADIAL ARTERY ACCESS
 Advantages of this technique include easy compressibility and
shorter times to ambulation. Before cannulation of the radial artery, it is
advisable to perform an Allen test to ensure the adequacy of ulnar
circulation to the hand. Another concern with radial artery cannulation is
the possible need for this artery as a bypass graft conduit in the future.
COMPLICATIONS
Complications of angiography are very rare. The following
complications have been reported occasionally.
1. Death
2. Myocardial ischemia
3. Cerebrovascular accident
4. Cardiac rhytm abnormalities
5. Contrast reactions
6. Cadiac perforation
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AIMS AND OBJECTIVE
1) To determine the prevalence of significant RAS in patients with
CAD
2) Correlation between severity of CAD and RAS
3) To determine the predictive factors associated with RAS. The
predictive factors studied are age, gender, smoking, hypertension,
diabetes mellitus, hypercholestrolemia, preprocedure serum
creatinine and extent of CAD.
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MATERIALS AND METHODS
SOURCE OF DATA
A sample of 100 CAD patients admitted for CAG in Government
Stanley Hospital, Chennai during the period June 2012 to November
2012.
TYPE OF STUDY:
-Observational study
INCLUSION CRITERIA
1) Suspected CAD was by ECG, Echo or TMT criteria
2) Creatinine clearance>60ml/min(By Cockroft and Gault equation)
3) Renal size of more than 9 cm on sonogram
EXCLUSION CRITERIA
1) Known case of RAS
2) Presence of single kidney
3) Known case of Chronic kidney disease
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METHOD OF DATA COLLECTION
CAD patients identified based on ECG, Echocardiography or TMT
criteria admitted for CAG in Government Stanley Hospital during the
period June 2012 to November 2012 were chosen for the study after
obtaining informed from the patients.
Demographic factors of the patients such as age, gender, smoking
habit, diabetes mellitus, hypertension, positive family history of CAD
were documented. The patient was subjected to blood investigations such
as hemoglobin, complete blood count, random blood sugar, blood urea,
serum creatinine, serum electrolytes, lipid profile. Creatinine clearance in
ml/min was calculated using the Cockroft and Gault formula,
Creainine clearance = (140-age) * (Wt in kg) * (0.85 if female) /
(72 * Cr)
Ultrasonogram abdomen was performed to look for the size of the
kidneys and the renal cortical echoes.
CAG  was  performed  by  the  radial  or  femoral  artery  approach  to
look for the sites(s) and extent of obstruction in the coronary vessels.
Simultaneously, a renal angiogram was performed during the procedure
to look for the presence of RAS, site of lesion, extent and whether
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unilateral or bilateral. Multivariate logistic regression analysis was used
to assess the relationship of the data.
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RESULTS
In the study, renal angiogram was done for100 CAD patients who
underwent CAG, to look for the presence of atherosclerotic renal artery
stenosis, the location and number of RAS sites involved.
Out of the 100 patients screened, 11 patients had no significant
CAD, 22 patients had single vessel disease, 31 patients had double vessel
disease and 36 patients had between triple vessel disease.
The patients in the study were aged between 42 and 70 years. 11
patients were aged between 42- 50 years, 55 patients 51- 60 years and 34
patients between 61- 70 years. In our study all patients found to have
were above age 60 years.
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PREVALENCE OF RAS IN CAD
Out of the patients screened, 14 patients had significant renal artery
stenosis, defined as a >50% obstruction of the renal artery lumen.
RAS
14%
NonRAS
86%
PREVALENCE OF RAS IN CAD
RAS
NonRAS
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LOCATION OF RAS
Out  of  the  14  patients  with  RAS,  4  patients  had  bilateral  renal
artery involvement while 10 patients had unilateral renal artery
involvement.
It was observed in previous studies that RAS was more frequent in
patients with multivessel disease which was reflected in our study also.
3 out of 14 patients had single vessel disease, 5 out of 11 patients had
double vessel disease and 6 out of 11 patients had triple vessel disease.
Bilateral, 4
Unilateral, 10
LOCATION OF RAS
Bilateral
Unilateral
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Using Pearson’s chi-square test (p=0.007), we can conclude that
the  extent  of  CAD is  significantly  associated  with  RAS at  0.01  level  of
significance.
ASSOCIATION OF RAS AND EXTENT OF CAD
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SITE OF RAS
Proximal renal artery stenosis has been previously observed to be
the  most  common  site  of  RAS.  In  our  study  too  it  was  observed  in  8
patients , and 3 patients had mid RAS and 3 patients had branch RAS.
Proximal, 8
Branch, 3
Mid, 3
SITE OF RAS
Proximal
Branch
Mid
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AGE AND CAD
The patients in the study were aged between 42 and 70 years. 11
patients were aged between 42- 50 years, 55 patients 51- 60 years and 34
patients between 61- 70 years.
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AGE AND RAS
In  our  study  all  patients  found  to  have  RAS  were  above  age  60
years.
GENDER DISTRIBUTION OF CAD
Out  of  the  100  CAD  patients  screened  34  patients  were  females
and 66 were males. CAD is known to have a higher prevalence in male
patients. Similar results were observed in our study.
Using Pearson’s chi-square test (p=0.151), we can conclude that
there is no significant association between gender and CAD at 0.01 level
of significance.
Male
66
Female
34
GENDER DISTRIBUTION IN CAD
Male
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GENDER DISTRIBUTION IN RAS
In our study RAS was much more common in males as compared
to females. 12 out of 14 patients with RAS were males.
Using Pearson’s chi-square test (p=0.103), we can conclude that
there is no significant association between gender and RAS at 0.01 level
of significance.
MALES, 12
FEMALES, 2
GENDER DISTRIBUTION IN RAS
MALES
FEMALES
65
HYPERTENSION AND CAD
Hypertension  is  a  known  risk  factor  for  CAD.  73  out  of  the  100
sample CAD patients were hypertensives.
Hypertensives
73
Non-
hypertensives
27
HYPERTENSION IN CAD
Hypertensives
Non-hypertensives
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HYPERTENSION & RAS
Like in CAD, RAS is more commonly seen in hypertensive
patients . 11 out of the 14 RAS patients were hypertensives.
Using Pearson’s chi-square test (p=0.657), we can conclude that
there is no significant association between hypertension and RAS at 0.01
level of significance.
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Nonhypertensive+RAS
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DIABETES MELLITUS AND CAD
Out of the 100 CAD patients studied, 64 patients were diabetic.
Diabetic, 64
Nondiabetic, 36
DIABETES MELLITUS AND CAD
Diabetic
Nondiabetic
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ASSOCIAION OF DIABETES MELLITUS AND RAS
Out of the 14 RAS patients in our study, 11 were diabetic patients
Using Pearson’s chi-square test (p=0.186), we can conclude that
there is no significant association between diabetes and RAS at 0.01 level
of significance.
3
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DIABETES MELLITUS & RAS
NonDiabetic+RAS
Diabetic+RAS
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SERUM CHOLESTEROL AND RAS
The  occurence  of  CAD  was  more  prevalent  among  patients  with
hypercholesterolemia. Serum cholesterol cut off value was taken as
200mg%. 52 out of the 100 patients had high cholesterol levels.
High
cholesterol, 52
Normal
cholesterol, 48
SERUM CHOLESTEROL & CAD
High cholesterol
Normal cholesterol
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ASSOCIATION OF SERUM CHOLESTEROL AND RAS:
Out of the 14 RAS patients, 12 patients had high cholesterol levels
while only 2 patients had normal cholesterol levels.
Normal
cholesterol, 2
High
cholesterol, 12
SERUM CHOLESTEROL AND RAS
Normal cholesterol
High cholesterol
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SMOKING AND CAD
68  out  of  the  100  CAD  patients  were  smokers.  Out  of  the  RAS
patients only 1 patient was a nonsmoker.
Using Pearson’s chi-square test (p=0.035), we can conclude that
there is no significant association between smoking and RAS at 0.01 level
of significance.
SMOKING AND RAS
Non smoker
Smoker
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MULTIVARIATE LOGISTIC REGRESSION
The following variables were found to be predictive at 0.01 level of
significance:
Variable Coefficient Significance
Age 0.655 0.001
Serum Creatinine 21.371 0.005
Creatinine Clearance 0.354 0.001
Lipid Profile 6.022 0.002
Extent of CAD 3.927 0.008
Thus in our study, age> 60 years (p=0.001), creatinine clearance
(p=0.001) lipid profile (p=0.002), serum creatinine (p=0.005) and extent
of CAD were observed to be significantly associated with RAS at 0.01
level of significance.
Male gender, hypertension, diabetes mellitus, smoking were
observed to be other independent risk factors.
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The logistic regression was obtained to be:
Probability(patient having RAS)=
1/(1+exp(-(-102.247+(0.655*Age)+(21.371*Serum Creatinine) +
(0.354*Creatinine Clearance)+(6.022*Lipid Profile)+(3.927*Extent
Of CAD)+(4.327*Hypertension)).
It was observed that if probability (patient having RAS) > 0.5,
patients were at a more risk of having RAS.
Using the above regression equation we were able to classify, 98%
of non-RAS patients (84 out of 85) and 80% of RAS patients (11 out of
14) correctly.
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DISCUSSION
Atherosclerotic  renal  artery stenosis  (ARAS) is  part  of  a  common
atherosclerotic phenomenon that occurs at multiple vascular sites in the
body. It can lead to potential complications discussed above and hence
early identification is important.
PREVALENCE OF ARAS
Our  study  demonstrates  the  total  prevalence  of  RAS  as  14%  in  a
screening renal angiogram performed during coronary angiography.
Cohen et al in 2005, screened the renal arteries in 843 patients who
underwent cardiac catheterization and found the prevalence of RAS to be
12%.[49] In the Buller et al study done in 2001-2002, 851 patients were
screened and renal atherosclerosis was observed in 332 patients.[50] In the
Salehi et al study done in 2011, 500 patients were screened and the
prevalence  of  RAS  was  found  to  be  25%.  Other  studies  have  also
demonstrated the prevalence of RAS to be ranging from 10-20%.
LOCATION OF RAS
In our study the prevalence of unilateral RAS was 10% and that of
bilateral RAS was 4%. In the Cohen et al study 84 patients had unilateral
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disease and 15 had patients had bilateral disease.[49] In  the  Buller  et  al
study severe bilateral stenosis was observed in 12 patients. [50]
Proximal renal artery stenosis has been previously observed to be
the most common site of RAS and the same was observed in our study. 8
out of the 14 RAS patients had proximal renal artery involvement.
CAD AND RAS
It has been previously reported that the occurrence of RAS was
found to be more frequent in multivessel CAD than single vessel disease.
The  same  was  seen  in  our  study.  11  out  of  the  14  RAS  patients  had
multivessel disease.
Previous studies have also reported the association of ARAS with
atherosclerotic disease in vascular territories other than the coronaries
including carotid artery disease and peripheral vascular disease. The
association could be explained by the common pathophysiologic
mechanism involving the renin angiotensin aldosterone system, altered
lipid levels and excess oxidative stress accelerating atherosclerosis at
various sites.
In  our  study  multivessel  CAD  is  associated  with  a  p  value  of
p=.008. In previous studies also it has been found that multivessel CAD
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is an independent risk factor for RAS. In the Cohen et al study it has been
found that the p value for association of RAS and multivessel disease is
0.40.[49] In the Buller et al study it has been concluded that the p value for
the association of RAS and multivessel disease is 0.041.[50]
AGE AND RAS
Old age (>60 years) was significantly associated with RAS in our
study population. Similar results have been obtained in previous studies.
This may demonstrate a delayed onset of atherosclerotic disease in renal
vessels. This has clinical implication as well. Screening renal
angiography can be restricted to patients >60 years instead of performing
them routinely in all patients.
GENDER PREVALENCE OF RAS
In most of the studies reported earlier, RAS has been more
commonly  seen  in  females.  But  in  our  study,  only  2  out  of  the  14  RAS
patients were females. However the association of gender an RAS is not
significant (p=0.151).
HYPERTENSION AND RAS
Hypertension has long been established as a predisposing cause
and a consequence of RAS. Hypertension was defined as blood pressure
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>140/90 mmHg in our study. 11 out of the 14 RAS patients were
hypertensives. Cohen et al study observed hypertension to be an
independent risk factor for ARAS and the p value for the association of
hypertension was found to be 0.011.[49] In the Buller et al study the
systolic blood pressure was significantly associated with ARAS with a p
value of 0.0001.[50] The diastolic blood pressure association with ARAS
was not significant (p value-0.4483).
DIABETES MELLITUS AND RAS
Diabetes mellitus has been identified to be an independent risk
factor for RAS previously reported studies including the Cohen e al and
Buller et al study. Even our study demonsrates the associaion of diabetes
mellitus and RAS but the associaion is not significant(p value-
0.497).[49,50]
SERUM CHOLESTEROL AND RAS
Out of the 14 RAS patients, 12 patients had high cholesterol levels
and hypercholesterolemia was observed to be significantly associated
with RAS(p=0.005). In the Cohen et al and the Buller et al study, though
hypercholesterolemia was observed to be a predictive factor, it was not
significantly associated with RAS.[49,50]
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CREATININE CLEARANCE AND RAS
The creatinine clearance in ml/min calculated by the Cockroft and
Gault formula was found to be significantly associated with RAS
(p=0.001).
The logistic regression of our study was obtained to be:
Probability(patient having RAS)=
1/(1+exp(-(-102.247+(0.655*Age)+(21.371*Serum Creatinine) +
(0.354*Creatinine Clearance)+(6.022*Lipid Profile)+(3.927*Extent
Of CAD)+(4.327*Hypertension)).
It was observed that if probability (patient having RAS) > 0.5,
patients were at a more risk of having RAS.
Using the above regression equation we were able to classify, 98%
of non-RAS patients (84 out of 85) and 80% of RAS patients (11 out of
14) correctly.
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The Cohen et  al  study has established Nomogram to calculate the
predictive score for significant RAS based on clinical profile of the
patients.[49] It is as below:
CLINICAL PARAMETER SCORE
AGE
< 64 years
64-72 years
>73 years
0
2
4
FEMALE SEX 2
HYPERTENSION 2
NO. OF CARDIAC DRUGS
None
1 drug
2 drugs
3drugs
0
1
3
4
PERIPHERAL VASCULAR
DISEASE
4
PREVIOUS MULTIVESSEL
DISEASE OR CABG
2
CREATININE (mg/dl)
<0.8
0.8-0.99
1-1.19
1.2-1.39
1.4-1.59
1.6-1.79
1.8-1.99
2-2.19
>2.20
0
1
3
4
6
7
9
10
12
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This score has enabled to stratify patients and determine the need
for renal angiogram. Patients having a score of 11 or more are chosen for
renal artery screening.
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CONCLUSIONS
? The true clinical occurrence of RAS is more than that reported.
? Early identification of patients having RAS can help to early
institution of treatment and hence prevention of long term
complications and better prognosis.
? In our study, age> 60 years (p=0.001), creatinine clearance
(p=0.001), lipid profile (p=0.002), serum creatinine (p=0.005),
extent of CAD (p=0.0080) were observed to be significantly
associated with ARAS at 0.01 level of significance.
? Male gender, hypertension, diabetes mellitus, smoking were
observed to be other independent risk factors.
? The logistic regression was obtained to be:
Probability (patient having RAS)=
1/(1+exp(-(-102.247+(0.655*Age)+(21.371*Serum Creatinine) +
(0.354*Creatinine Clearance)+(6.022*Lipid Profile) + (3.927*
Extent Of CAD) + (4.327 * Hypertension)).
It was observed that if probability (patient having RAS) > 0.5,
patients were at a more risk of having RAS.
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LIMITATIONS OF THE STUDY
- The impact of clinical identification of incidental RAS on the long
term outcome of the patient has not been studied.
- Being done in a single centre there may be referral bias.
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PROFORMA
Name:
Age/ sex:
Educational status:  Occupation:
Marital status:
Address:
Contact number:
CLINICAL FEATURES: DURATION
1) Difficulty in breathing
2) Chest pain
3) Syncope
4) Cough
5) Oliguria
6) Leg swelling
7) Facial puffiness
8) Fatiguability
9) Abdominal pain/ distension
10) Altered sensorium
94
PAST HISTORY:
IHD...................................(duration........; treatment...........)
Renal disease...................................(duration........; treatment...........)
Hypertension...................(duration.......; treatment............)
Diabetes mellitus.............(duration.......; treatment............)
Stroke..............................(duration.......; treatment............)
Other significant past history:
PERSONAL HISTORY:
Diet: vegetarian/ non- vegetarian/ mixed/ fruits/ fast food
Appetite- good/ poor
Bowel- normal/ constipation/ loose stools
Bladder- normal/ polyuria/ oliguria
Sleep- normal/ reduced
Mental stress- low/ mod/ high
Smoking- smoker
 Ex- smoker (quit since...........)
Alcohol- duration- Unit-
Tobacco-
Exercise-
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TREATMENT HISTORY:
FAMILY HISTORY:
Coronary artery disease
Hypertension
Diabetes mellitus
Stroke
Renal disease
GENERAL PHYSICAL EXAMINATION:
Pallor
Cyanosis
Clubbing
Icterus
Pedal edema
Lymphadenopathy
VITAL SIGNS:
Temperature (in F):
Pulse (/ min):
BP ( mm of Hg):
Pulse pressure (mm of Hg):
Respiratory rate:
96
SYSTEMIC EXAMINATION:
CVS:
RS:
PA:
CNS:
INVESTIGATIONS:
ECG: ECHO:
CXR:
CBC:
TC-  DC-  Hb-  ESR-  Platelet-
BLOOD SUGAR:
RBS- FBS- PPBS-
LIPID PROFILE-
VLDL-  LDL- HDL- Total
Cholesterol- TGL-
RENAL PARAMETERS-
Blood urea-
Serum creatinine-
Sr.Na- Sr.K- Sr.Cl- Sr. HCO3-
URINE-
Sugar- Protein-
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Cells/ casts-
ULTRASOUND ABDOMEN-
CAG REPORT:
SITE(S):
EXTENT:
NUMBER OF VESSELS INVOLVED:
RENAL ANGIOGRAM REPORT:
SITE:
EXTENT:
UNILATERAL/ BILATERAL:
OTHER INVESTIGATIONS:
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CONSENT FORM
(1) I agree to {permit my relative(mention relation)} participate in the
study  entitled,  “Prevalence and predictors of Renal artery
stenosis (RAS) in coronary artery disease (CAD) patients
undergoing Coronary angiogram (CAG) in Government
Stanley Hospital, Chennai”.
(2 )  I confirm that i have been told about this study to be conducted on
my relative in my mother tongue and have had the opportunity to
ask questions.
(3) I understand that the participation is voluntary and we may refuse
to participate at any time without giving reasons and without
affecting my benefits.
(4) I agree not to restrict the use of any data or results that may arise
from this study.
Name of the participant: Sign/ thumbprint:
Name of the relative: Sign/ thumbprint:
Relationship:
Sign of the investigator:
99
100

Sr. No Age Weight Sex Hypertension Diabetes mellitus Sr. creatinine
Estimate creatinine clearance
(ml/min) Lipid profile Smoking Family History RAS UL/BL Site of RAS
Extent of CAD
(no. of vessels)
1 54 65 1 1 0 0.9 86.3 1 1 1 0 1
2 50 68 1 1 1 1 85 0 0 0 0 2
3 52 70 0 1 1 0.8 69.5 0 1 0 0 0
4 65 74 1 1 0 1 86.3 1 1 0 1 0 proximal 0
5 58 76 0 1 1 1 73.6 0 1 0 0 1
6 55 60 1 1 0 0.9 78.7 0 0 0 0 0
7 56 63 1 0 1 0.8 91.9 1 1 1 0 1
8 55 70 0 1 0 1 70.2 0 1 0 0 0
9 64 72 1 0 1 1.1 69.1 0 1 0 0 0
10 68 70 1 1 1 1.1 72.5 1 1 0 1 1 proximal 0
11 59 66 1 1 1 0.8 92.8 1 1 0 0 0
12 68 67 0 1 0 0.9 63.3 1 1 1 0 1
13 69 72 1 0 1 0.9 78.9 1 0 0 0 0
14 55 70 0 1 0 1.1 63.9 0 0 0 0 2
15 66 60 1 1 0 0.8 77.1 1 1 0 0 0
16 60 64 1 1 1 0.8 88.9 1 1 1 0 1
17 59 68 0 1 1 1 65 0 0 0 0 0
18 58 65 1 1 1 0.9 82.3 1 1 0 0 0
19 62 72 1 0 1 0.8 112.5 1 1 1 1 0 branch 0
20 56 80 0 1 0 0.9 88.1 1 1 0 0 1
21 55 81 1 1 1 1 95.6 0 0 1 0 0
22 49 68 0 1 1 1.1 68.1 0 1 0 0 1
23 48 60 1 0 0 0.7 109.5 0 1 0 0 0
24 60 62 1 1 0 0.9 76.5 1 1 0 0 2
25 62 72 0 1 1 1 66.3 1 0 1 0 2
26 49 82 1 1 1 1.1 95.3 0 1 1 0 0
27 56 79 0 1 0 1.1 71.2 1 1 1 0 0
28 58 80 1 0 1 1.2 75.9 0 0 1 0 0
29 44 69 1 1 1 0.9 102.2 1 1 0 0 2
30 48 70 0 0 1 0.8 95 0 1 0 0 0
31 65 74 0 1 0 1 72.5 1 1 0 1 1 branch 1
32 65 75 1 1 1 0.9 78.4 1 0 1 0 0
33 63 88 1 1 1 1.2 78.4 0 1 1 0 0
34 62 69 0 0 1 1 63.5 1 1 0 0 1
35 64 73 1 1 0 1 77.1 0 1 0 0 0
36 55 72 0 1 0 0.9 73.3 1 1 1 0 0
37 57 70 1 0 0 0.8 100.9 0 0 1 0 0
38 50 66 0 1 1 1 82.5 1 1 1 0 1
39 62 76 1 1 1 1 76.3 1 1 1 1 0 proximal 1
40 60 69 1 1 1 0.9 85.2 1 1 0 0 0
41 58 60 0 1 1 0.9 64.5 0 0 0 0 1
42 55 72 1 0 0 1 85 1 1 1 0 0
43 56 66 0 1 0 0.9 85.6 0 1 1 0 0
44 49 74 1 1 0 0.8 116.9 1 1 0 0 0
45 68 78 1 0 1 1 106.2 0 1 0 1 1 branch 1
46 67 60 1 1 1 0.8 76 0 0 1 0 1
47 68 79 1 1 0 1.1 83.8 0 1 1 0 0
48 62 66 0 0 1 1 71.5 0 1 0 0 0
49 63 77 1 1 1 1.1 74.9 0 1 1 0 1
50 63 78 1 1 1 0.9 91.7 1 1 1 1 0 mid 0
51 65 63 1 1 1 0.8 91.9 1 1 0 1 1 mid 0
52 66 65 1 1 1 0.7 95.4 1 0 0 0 0
53 65 72 1 1 1 0.9 83.3 0 1 1 0 1
54 68 72 0 1 0 0.9 68 0 1 1 0 2
55 70 79 1 1 0 1 76.8 0 0 0 0 0
56 67 72 1 0 1 0.8 92.1 1 1 1 1 0 mid 0
57 67 76 1 1 1 1 77.1 0 0 1 0 1
58 64 76 0 1 1 1 68.2 0 1 1 0 0
59 60 69 1 1 1 0.9 85.2 1 1 0 0 0
60 57 71 1 1 0 1.1 74.4 0 0 0 0 2
61 56 75 1 0 1 0.9 97.2 1 1 1 0 0
62 47 69 0 1 1 0.9 84.2 0 1 1 0 1
63 48 77 1 1 0 1.1 89.4 1 1 1 0 0
64 50 66 1 1 1 1 82.5 0 1 1 0 0
65 66 74 1 1 1 0.8 82.2 1 0 0 1 0 proximal 0
66 52 60 0 1 1 0.8 77.9 0 1 0 0 0
67 55 62 1 0 1 0.8 91.5 1 1 0 0 0
68 57 81 1 1 1 0.9 103.8 0 0 0 0 0
69 58 80 0 1 0 1.2 64.5 0 1 0 0 0
70 59 68 1 1 1 1.1 69.5 1 1 1 0 0
71 60 69 1 1 1 0.9 85.2 1 1 0 1 0 proximal 0
72 65 72 1 1 1 1.1 68.2 1 0 0 0 0
73 69 70 0 1 1 1.1 53.3 1 1 0 0 1
74 63 66 1 0 0 1 70.6 0 0 1 0 0
75 58 62 1 0 0 1 70.6 1 1 0 0 0
76 53 63 0 1 0 0.9 71.9 0 1 0 0 1
77 52 64 1 1 1 0.8 97.8 0 1 0 0 0
78 51 70 1 1 1 1.1 78.7 1 0 1 0 0
79 56 72 0 0 0 1.2 59.5 0 0 0 0 2
80 54 82 1 1 0 1.2 81.6 1 1 0 0 0
81 55 84 0 0 1 1.2 82.6 0 1 0 0 0
82 68 68 1 0 1 0.9 75.6 1 1 0 0 1
83 67 69 0 1 0 0.9 74.2 1 1 1 1 0 proximal 0
84 63 70 1 1 1 1 74.9 0 0 0 0 0
85 62 76 1 0 1 1 82.3 1 1 0 0 0
86 63 70 0 0 1 1.1 57.8 0 0 0 0 0
87 59 80 1 1 0 1.2 75 0 0 0 0 0
88 58 84 1 1 0 1.2 79.7 0 0 0 0 0
89 42 60 1 0 0 0.9 90.7 1 1 1 0 2
90 68 70 0 1 1 1.2 49.6 1 1 0 0 0
91 61 82 1 1 1 1.2 75 0 1 0 1 0 proximal 0
92 66 69 1 1 1 1.1 64.5 0 0 0 0 0
93 46 63 1 1 0 0.9 91.4 1 0 0 0 2
94 48 67 1 0 0 0.9 95.1 0 0 0 0 0
95 64 72 0 0 1 1 64.6 1 1 0 0 0
96 62 76 1 1 1 1.2 68.6 1 1 1 1 0 proximal 0
97 62 78 1 1 1 1.2 70.4 1 1 0 0 0
98 56 80 0 1 0 1.2 77.8 0 0 0 0 1
99 54 69 0 0 1 0.9 77.8 1 0 1 0 2
100 64 72 0 0 1 1 64.6 1 0 0 0
Age in yrs Wt. in kg
1 - Male
0 - Female
E - Hypertension
1 - Present
0 - Absent
Diabetes Mellitus
1 - Present
0 - Absent
Serum
creatinine
(mg%)
Creatinine clearance
(ml/minute)
Cockroft Gault formula
Serum
Cholesterol
1 - High
0 - Normal
Smoking
1 - Present
0 - Absent
Family History
1 - Present
0 - Absent
RAS
1 - Present
0 - Absent
Location of
RAS
1 - Bilateral
0 - Unilateral
Site of RAS
1 - Bilateral
0 - Unilateral
Extent of CAD
0 - Multivessel
1 - Single vessel
2 - No significant CAD
